Log in  First Connection?

Oncology ImagingArchives

Tamoxifen-loaded TPGS-PLGA nanoplatform for breast cancer therapy: insights into drug delivery, distribution, treatment efficacy, and ultrasound/photoacoustic imaging

 Published on 21/04/2026 |  Original article (Full-text)  | Dipali Patil et al. | Nanomedicine 2026; 21(5): 663-674

The of the present study was to develop and characterize tamoxifen (TAM)-loaded TPGS-PLGA nanoparticles (NPs) for more effective breast cancer treatment than conventional therapy. TAM@TPGS-PLGA-NPs were developed using the emulsion-solvent evaporation method. Furthermore, various physicochemical characterizations...

Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer

 Published on 14/04/2026 |  Original article (Full-text)  | Yuki Tominaga et al. | Journal of Radiation Research. Volume 67(2).

This study evaluated the feasibility of pencil beam scanning (PBS) proton therapy for stereotactic body radiotherapy using an isodose prescription in patients with isolated early-stage lung cancer, comparing dose-volume metrics with those of volumetric modulated arc therapy (VMAT). Treatment plans were...

ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer

 Published on 07/04/2026 |  Original article (Full-text)  | Emma L O'Dowd et al. | European journal of cardio-thoracic surgery. Volume 64(4).

Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative now is to ensure that implementation follows an evidence-based process that...

A rare primary mediastinal mesenchymal tumor diagnosed by endobronchial ultrasound (EBUS)

 Published on 31/03/2026 |  Original article (Full-text)  | Argun Baris Serap et al. | BMC Pulmonary Medicine 2026; 26(1): 60

Mesenchymal tumors of the mediastinum are exceedingly rare, accounting for only approximately 2–6% of all mediastinal neoplasms [1]. Except for certain exceptions, mediastinal soft tissue tumors display histological and molecular features largely analogous to those of their counterparts in other...

Oncology Imaging
 NaN min.

 Published on 14/11/2024 |  Original article (Full-text)  |